Phase I-B results for nintedanib DPI in IPF patients showed strong safety and tolerability, with no serious adverse events or GI issues and only mild, transient cough in a minority of patients. The Technosphere DPI platform achieved efficient lung delivery, supporting advancement to a global phase II trial evaluating both monotherapy and combination use.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.